Search fresh public links, source activity, and ready-to-use post angles for Scribe Therapeutics.
Fresh curated links around Scribe Therapeutics are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
In vivo gene editing outfit Scribe Therapeutics has priced its IPO at $128.7 million, surpassing the $96 million goal set out earlier this week.
Scribe Therapeutics’ IPO will support a pipeline led by a genetic medicine that represses expression of its target gene without making permanent changes. Common chronic cardiometab...
Scribe Therapeutics has put its IPO plans down on paper, showing the genetic medicine company hopes to raise $96 million through its public listing.
The startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most other biotech companies that have gone public in 2026.
The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years.
Schrödinger announced the launch of new immune disease-focused Tectora Therapeutics, which comes online with a $55 million series A financing round.
How synthetic DNA and RNA are becoming the discovery engines behind a new generation of precision therapies. The post Rewriting Disease: Oligonucleotides Take Aim at the Untreatabl...
Through its entry into Lilly Gateway Labs, Rznomics officials say they plan to accelerate candidate discovery and development across its target gene database bank comprising over 2...
The PROPEL program aims to control gene expression through RNA structure, building logic-gated RNA therapies that switch on only where and when intended, without altering the genom...
Most recently the leader of buzzy startup Tessera Therapeutics, Severino will look to improve the fortunes of a company facing emerging competition and declining sales for its priz...
The collaboration is specifically focused on applying Receptor.AI's computational platform to Sethera's proprietary polymacrocyclic peptide chemistry, encoded screening data, and r...
The startup has completed enrollment of an early-stage study testing a first-of-its-kind treatment for facioscapulohumeral muscular dystrophy, a disease targeted by many other drug...
Led by serial biotech entrepreneur Greg Verdine, the startup mined fungi genomes to find a safer alternative to the drugs widely used to prevent the body from rejecting transplante...
A preclinical study showed how chemically enhanced suppressor tRNAs combined with a lung-targeted delivery system can restore production of a critical protein in models of cystic f...
Epicrispr Biotechnologies has raised $90 million in a series C round backed by investors including Sanofi Ventures, positioning the biotech to advance a pipeline of epigenetic medi...
New research coming out of the University of Toronto has shown that transfer RNA may offer a promising therapeutic avenue for treating genetic diseases.
DNA Script says the company is contributing its EDS technology and acting as a technical solution integrator for the project, while adapting its solution to incorporate GE HealthCa...
Skye Bioscience has entered into an agreement to combine with privately held fibrotic disease biotech Redx Pharma in a deal that will net $125 million in financing for the new publ...
The Bengaluru-based company has built three CRISPR platforms covering molecular diagnostics, gene editing and disease modelling, and is commercialising the diagnostics one first.
Unlike prediction-based approaches, Broken String Biosciences says BaseMap ABE generates genome-wide data directly from biologically relevant cells, providing researchers with clea...
The Palo Alto-based company is developing small molecule drugs that modulate the transcriptome. The latest funding raise will advance IND-enabling studies and clinical preparation...
The collaboration brings together Synastra’s expertise in genomic engineering, AAV vector design, rare-disease gene therapy, and translational development with NewBiologix’s propri...
Avenue Biosciences´ machine learning-powered platform engineers and screens signal peptide variants to increase protein secretion from cells. Circio’s circVec technology has demons...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.